CS Diagnostics Corp.
0.3600+0.02 (+5.26%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCQB · CSDX · USD
Key Stats
Market Cap
49.44MP/E (TTM)
-Basic EPS (TTM)
-1869295.40Dividend Yield
0%Recent Filings
8-K
CS Diagnostics unveils hydrogel innovation
CS Diagnostics Corp. spotlighted its role in the CS Group, emphasizing innovative medical distribution for patient care. The company highlights CS Protect Hydrogel, a spacer gel that separates healthy from malignant tissues in radiation therapy, boosting recovery odds for prostate cancer patients while enhancing safety and quality of life. Future products undergo rigorous testing. Its global reach aids regulatory approvals and collaborations worldwide.
10-Q
Q3 FY2009 results
FlashZero Corp. posted no revenue for Q3 ended September 30, 2009, mirroring the prior year, while operating expenses climbed to $67,449 from $40,682 y/y, driven by higher general and administrative costs, yielding an operating loss of $67,449 versus $40,682 y/y. Net loss widened to $67,449 from $56,146 y/y, with the gap attributable to absent other expenses this quarter. For the nine months, net loss narrowed to $202,345 from $361,497 y/y amid lower expenses. Cash held steady at $37,381, but liabilities swelled to $1,794,932 from $1,603,889 y/y, underscoring liquidity strains. No free cash flow disclosed in the 10-Q. Ongoing legal battles pose persistent risks.
10-Q
Q1 FY2009 results
FlashZero Corp. posted zero revenue for Q1 2009 ended March 31, while operating expenses dropped 59% y/y to $67,449 (derived), yielding an operating loss of $67,449—better than the $163,816 loss a year earlier. Net loss narrowed to $67,449 from $176,452, with the prior-year gap to operating loss tied to $12,636 in other expenses. Diluted EPS improved to $(0.002) on 48,286,306 shares, matching basic and reconciling without anti-dilution effects. Cash held steady at $37,381, but liabilities climbed to $1,671,338 amid ongoing legal battles like the SEC fraud case and unpaid fees suits. No free cash flow disclosed in the 10-Q. Ongoing litigation poses persistent risks.
10-K
FY2008 results
FlashZero Corp., formerly The Children's Internet, Inc., reported no revenue for FY2008 ended December 31, 2008, down from $664 in 2007, amid a development-stage halt in operations after taking its child-safe internet service offline in January 2008 to cut costs. The net loss narrowed to $401,629 from $1,165,988 year-over-year, driven by a 68% drop in general and administrative expenses to $355,195, while operating cash burn reached $727,607. Q4 showed no quarterly breakdowns, but the full-year trend reflected suspended sales and minimal activity, with shares outstanding rising to 48,286,306 from 31,373,738 via issuances for services and debt extinguishment. Liquidity remained tight at $37,381 in cash against $1.6 million in liabilities, funded by $742,463 in financing inflows. No annual guidance was provided. Ongoing SEC litigation over alleged investor fraud poses a key risk to any operational restart.
10-Q
Q2 FY2009 results
FlashZero Corp. posted a narrower net loss of $67,448 for Q2 2009 ended June 30, down from $128,899 a year earlier, while the six-month loss of $134,896 improved from $305,351 y/y, driven by lower general and administrative expenses of $67,448 versus $113,741 (derived). No revenue materialized in either period, leaving gross margins undefined. Operating losses mirrored net figures with no taxes or other major items; the net loss aligns with diluted EPS of $0.003 on 26,873,738 weighted shares, though balance sheet shares hit 48,286,306, flagging potential anti-dilution effects. Cash stayed flat at $37,381, with net operating cash use of zero but liabilities climbing to $1,738,786 from $1,603,889 q/q, underscoring liquidity strain. Ongoing SEC litigation poses a persistent regulatory risk.
BIO
Bio-Rad Laboratories, Inc.
319.47-10.95
CDIX
CARDIFF LEXINGTON CORPORATION
1.01+0.00
CERS
Cerus Corporation
1.45-0.05
CODX
Co-Diagnostics, Inc.
0.49-0.08
CTSO
Cytosorbents Corporation
0.78-0.05
HSDT
Solana Company
6.78+0.17
LUCD
Lucid Diagnostics Inc.
1.25-0.02
SRDX
Surmodics, Inc.
26.93-0.43
SSMXF
Sysmex Corp.
10.84+0.00
WGS
GeneDx Holdings Corp.
131.76-5.71